ID   MEF2A_HUMAN             Reviewed;         507 AA.
AC   Q02078; O43814; Q14223; Q14224; Q59GX4; Q96D14;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   21-MAR-2012, entry version 124.
DE   RecName: Full=Myocyte-specific enhancer factor 2A;
DE   AltName: Full=Serum response factor-like protein 1;
GN   Name=MEF2A; Synonyms=MEF2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS MEF2; RSRFC4 AND RSRFC9),
RP   DNA-BINDING, TISSUE SPECIFICITY, AND DIMERIZATION.
RC   TISSUE=Placenta;
RX   MEDLINE=92084105; PubMed=1748287;
RA   Pollock R., Treisman R.;
RT   "Human SRF-related proteins: DNA-binding properties and potential
RT   regulatory targets.";
RL   Genes Dev. 5:2327-2341(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM RSRFC9), AND SEQUENCE REVISION.
RA   Treisman R.;
RL   Submitted (NOV-1993) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS MEF2 AND RSRFC9), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Heart, and Skeletal muscle;
RX   MEDLINE=92387551; PubMed=1516833;
RA   Yu Y.-T., Breitbart R.E., Smoot L.B., Lee Y., Mahdavi V.,
RA   Nadal-Ginard B.;
RT   "Human myocyte-specific enhancer factor 2 comprises a group of tissue-
RT   restricted MADS box transcription factors.";
RL   Genes Dev. 6:1783-1798(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS RSRFC4 AND RSRFC9).
RA   Suzuki E., Lowry J., Sonoda G., Testa J.R., Walsh K.;
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno F.R.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH MAPK7, AND PHOSPHORYLATION.
RX   MEDLINE=98428659; PubMed=9753748; DOI=10.1093/nar/26.20.4771;
RA   Yang C.-C., Ornatsky O.I., McDermott J.C., Cruz T.F., Prody C.A.;
RT   "Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-
RT   activated protein kinase, ERK5/BMK1.";
RL   Nucleic Acids Res. 26:4771-4777(1998).
RN   [8]
RP   INTERACTION WITH HDAC4 AND HDAC9.
RX   MEDLINE=99417590; PubMed=10487761; DOI=10.1093/emboj/18.18.5099;
RA   Miska E.A., Karlsson C., Langley E., Nielsen S.J., Pines J.,
RA   Kouzarides T.;
RT   "HDAC4 deacetylase associates with and represses the MEF2
RT   transcription factor.";
RL   EMBO J. 18:5099-5107(1999).
RN   [9]
RP   PHOSPHORYLATION AT THR-312; THR-319 AND SER-453, FUNCTION,
RP   HETERODIMERIZATION, AND MUTAGENESIS OF THR-312; THR-319; SER-355;
RP   SER-453 AND SER-479.
RX   PubMed=9858528;
RA   Zhao M., New L., Kravchenko V.V., Kato Y., Gram H., di Padova F.,
RA   Olson E.N., Ulevitch R.J., Han J.-D.;
RT   "Regulation of the MEF2 family of transcription factors by p38.";
RL   Mol. Cell. Biol. 19:21-30(1999).
RN   [10]
RP   INTERACTION WITH MAPK14, PHOSPHORYLATION AT THR-312 AND THR-319, AND
RP   MUTAGENESIS OF ARG-269; LYS-270; LEU-273; VAL-275; ILE-277 AND
RP   PRO-278.
RX   PubMed=10330143;
RA   Yang S.-H., Galanis A., Sharrocks A.D.;
RT   "Targeting of p38 mitogen-activated protein kinases to MEF2
RT   transcription factors.";
RL   Mol. Cell. Biol. 19:4028-4038(1999).
RN   [11]
RP   PHOSPHORYLATION AT THR-312; THR-319 AND SER-355, AND MUTAGENESIS OF
RP   THR-312; THR-319 AND SER-355.
RX   PubMed=10849446; DOI=10.1074/jbc.M001573200;
RA   Kato Y., Zhao M., Morikawa A., Sugiyama T., Chakravortty D., Koide N.,
RA   Yoshida T., Tapping R.I., Yang Y., Yokochi T., Lee J.D.;
RT   "Big mitogen-activated kinase regulates multiple members of the MEF2
RT   protein family.";
RL   J. Biol. Chem. 275:18534-18540(2000).
RN   [12]
RP   PROTEOLYTIC PROCESSING AT ASP-176; ASP-213 AND ASP-466, FUNCTION, AND
RP   MUTAGENESIS OF ASP-176 AND ASP-213.
RX   PubMed=11904443; DOI=10.1073/pnas.022036399;
RA   Okamoto S., Li Z., Ju C., Scholzke M.N., Mathews E., Cui J.,
RA   Salvesen G.S., Bossy-Wetzel E., Lipton S.A.;
RT   "Dominant-interfering forms of MEF2 generated by caspase cleavage
RT   contribute to NMDA-induced neuronal apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:3974-3979(2002).
RN   [13]
RP   PHOSPHORYLATION AT SER-255; THR-312; THR-319 AND SER-408, MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF SER-255.
RX   PubMed=12586839; DOI=10.1074/jbc.M211312200;
RA   Cox D.M., Du M., Marback M., Yang E.C.C., Chan J., Siu K.W.M.,
RA   McDermott J.C.;
RT   "Phosphorylation motifs regulating the stability and function of
RT   myocyte enhancer factor 2A.";
RL   J. Biol. Chem. 278:15297-15303(2003).
RN   [14]
RP   PHOSPHORYLATION AT SER-408, FUNCTION, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF SER-408.
RX   PubMed=12691662; DOI=10.1016/S0896-6273(03)00191-0;
RA   Gong X., Tang X., Wiedmann M., Wang X., Peng J., Zheng D.,
RA   Blair L.A.C., Marshall J., Mao Z.;
RT   "Cdk5-mediated inhibition of the protective effects of transcription
RT   factor MEF2 in neurotoxicity-induced apoptosis.";
RL   Neuron 38:33-46(2003).
RN   [15]
RP   INTERACTION WITH SLC2A4RG.
RX   PubMed=14630949; DOI=10.1073/pnas.2432756100;
RA   Knight J.B., Eyster C.A., Griesel B.A., Olson A.L.;
RT   "Regulation of the human GLUT4 gene promoter: interaction between a
RT   transcriptional activator and myocyte enhancer factor 2A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:14725-14730(2003).
RN   [16]
RP   FUNCTION OF BETA DOMAIN.
RX   PubMed=15834131; DOI=10.1074/jbc.M502491200;
RA   Zhu B., Ramachandran B., Gulick T.;
RT   "Alternative pre-mRNA splicing governs expression of a conserved
RT   acidic transactivation domain in myocyte enhancer factor 2 factors of
RT   striated muscle and brain.";
RL   J. Biol. Chem. 280:28749-28760(2005).
RN   [17]
RP   PROTEOLYTIC PROCESSING, AND PHOSPHORYLATION.
RX   PubMed=15888658; DOI=10.1523/JNEUROSCI.1331-05.2005;
RA   Tang X., Wang X., Gong X., Tong M., Park D., Xia Z., Mao Z.;
RT   "Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of
RT   the transcription factor myocyte enhancer factor 2.";
RL   J. Neurosci. 25:4823-4834(2005).
RN   [18]
RP   ACETYLATION.
RX   PubMed=15831463; DOI=10.1128/MCB.25.9.3575-3582.2005;
RA   Ma K., Chan J.K., Zhu G., Wu Z.;
RT   "Myocyte enhancer factor 2 acetylation by p300 enhances its DNA
RT   binding activity, transcriptional activity, and myogenic
RT   differentiation.";
RL   Mol. Cell. Biol. 25:3575-3582(2005).
RN   [19]
RP   SUMOYLATION AT LYS-403, INTERACTION WITH PIAS1, FUNCTION, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-403.
RX   PubMed=16563226; DOI=10.1111/j.1582-4934.2006.tb00295.x;
RA   Riquelme C., Barthel K.K., Liu X.;
RT   "SUMO-1 modification of MEF2A regulates its transcriptional
RT   activity.";
RL   J. Cell. Mol. Med. 10:132-144(2006).
RN   [20]
RP   SUMOYLATION AT LYS-403, PHOSPHORYLATION AT SER-408, FUNCTION, AND
RP   MUTAGENESIS OF LYS-403 AND SER-408.
RX   PubMed=16371476; DOI=10.1073/pnas.0503698102;
RA   Hietakangas V., Anckar J., Blomster H.A., Fujimoto M., Palvimo J.J.,
RA   Nakai A., Sistonen L.;
RT   "PDSM, a motif for phosphorylation-dependent SUMO modification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:45-50(2006).
RN   [21]
RP   PHOSPHORYLATION AT SER-408, AND FUNCTION.
RX   PubMed=16484498; DOI=10.1126/science.1122513;
RA   Shalizi A., Gaudilliere B., Yuan Z., Stegmueller J., Shirogane T.,
RA   Ge Q., Tan Y., Schulman B., Harper J.W., Bonni A.;
RT   "A calcium-regulated MEF2 sumoylation switch controls postsynaptic
RT   differentiation.";
RL   Science 311:1012-1017(2006).
RN   [22]
RP   PHOSPHORYLATION AT THR-312 BY NLK.
RX   PubMed=17785444; DOI=10.1128/MCB.01481-07;
RA   Satoh K., Ohnishi J., Sato A., Takeyama M., Iemura S., Natsume T.,
RA   Shibuya H.;
RT   "Nemo-like kinase-myocyte enhancer factor 2A signaling regulates
RT   anterior formation in Xenopus development.";
RL   Mol. Cell. Biol. 27:7623-7630(2007).
RN   [23]
RP   ACETYLATION, AND INVOLVEMENT IN CARDIAC HYPERTROPHY.
RX   PubMed=18697823; DOI=10.1161/CIRCULATIONAHA.107.760488;
RA   Wei J.Q., Shehadeh L.A., Mitrani J.M., Pessanha M., Slepak T.I.,
RA   Webster K.A., Bishopric N.H.;
RT   "Quantitative control of adaptive cardiac hypertrophy by
RT   acetyltransferase p300.";
RL   Circulation 118:934-946(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-235 AND SER-255, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-235, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-249, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [27]
RP   VARIANTS SER-263; LEU-279 AND ASP-283, AND CHARACTERIZATION OF
RP   VARIANTS SER-263; LEU-279 AND ASP-283.
RX   PubMed=15496429; DOI=10.1093/hmg/ddh329;
RA   Bhagavatula M.R.K., Fan C., Shen G.-Q., Cassano J., Plow E.F.,
RA   Topol E.J., Wang Q.;
RT   "Transcription factor MEF2A mutations in patients with coronary artery
RT   disease.";
RL   Hum. Mol. Genet. 13:3181-3188(2004).
RN   [28]
RP   VARIANT LEU-279, AND ASSOCIATION WITH SUSCEPTIBILITY TO MYOCARDIAL
RP   INFARCTION.
RX   PubMed=15958500; DOI=10.1136/jmg.2005.035071;
RA   Gonzalez P., Garcia-Castro M., Reguero J.R., Batalla A., Ordonez A.G.,
RA   Palop R.L., Lozano I., Montes M., Alvarez V., Coto E.;
RT   "The Pro279Leu variant in the transcription factor MEF2A is associated
RT   with myocardial infarction.";
RL   J. Med. Genet. 43:167-169(2006).
RN   [29]
RP   VARIANT LEU-279, AND LACK OF ASSOCIATION WITH MYOCARDIAL INFARCTION.
RX   PubMed=18086930; DOI=10.1161/CIRCULATIONAHA.107.728485;
RA   Lieb W., Mayer B., Koenig I.R., Borwitzky I., Goetz A., Kain S.,
RA   Hengstenberg C., Linsel-Nitschke P., Fischer M., Doering A.,
RA   Wichmann H.E., Meitinger T., Kreutz R., Ziegler A., Schunkert H.,
RA   Erdmann J.;
RT   "Lack of association between the MEF2A gene and myocardial
RT   infarction.";
RL   Circulation 117:185-191(2008).
RN   [30]
RP   STRUCTURE BY NMR OF 2-86 IN COMPLEX WITH DNA.
RX   PubMed=10835359; DOI=10.1093/emboj/19.11.2615;
RA   Huang K., Louis J.M., Donaldson L., Lim F.L., Sharrocks A.D.,
RA   Clore G.M.;
RT   "Solution structure of the MEF2A-DNA complex: structural basis for the
RT   modulation of DNA bending and specificity by MADS-box transcription
RT   factors.";
RL   EMBO J. 19:2615-2628(2000).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 2-78 IN COMPLEX WITH DNA, AND
RP   DIMERIZATION.
RX   PubMed=10715212; DOI=10.1006/jmbi.2000.3568;
RA   Santelli E., Richmond T.J.;
RT   "Crystal structure of MEF2A core bound to DNA at 1.5 A resolution.";
RL   J. Mol. Biol. 297:437-449(2000).
CC   -!- FUNCTION: Transcriptional activator which binds specifically to
CC       the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-
CC       specific genes. Also involved in the activation of numerous growth
CC       factor- and stress-induced genes. Mediates cellular functions not
CC       only in skeletal and cardiac muscle development, but also in
CC       neuronal differentiation and survival. Plays diverse roles in the
CC       control of cell growth, survival and apoptosis via p38 MAPK
CC       signaling in muscle-specific and/or growth factor-related
CC       transcription. In cerebellar granule neurons, phosphorylated and
CC       sumoylated MEF2A represses transcription of NUR77 promoting
CC       synaptic differentiation.
CC   -!- SUBUNIT: Binds DNA as a homo- or heterodimer. Dimerizes with
CC       MEF2D. Interacts with HDAC7 (By similarity). Interacts with PIAS1;
CC       the interaction enhances sumoylation. Interacts with HDAC4, HDAC9
CC       and SLC2A4RG. Interacts (via the N-terminal) with MAPK7; the
CC       interaction results in the phosphorylation and transcriptional
CC       activity of MEF2A.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=MEF2;
CC         IsoId=Q02078-1; Sequence=Displayed;
CC       Name=MEFA;
CC         IsoId=Q02078-2; Sequence=VSP_006240;
CC       Name=RSRFC4;
CC         IsoId=Q02078-3; Sequence=VSP_006241, VSP_006242;
CC       Name=RSRFC9;
CC         IsoId=Q02078-4; Sequence=VSP_006240, VSP_006241, VSP_006242;
CC       Name=5;
CC         IsoId=Q02078-5; Sequence=VSP_006241;
CC         Note=No experimental confirmation available;
CC       Name=6;
CC         IsoId=Q02078-6; Sequence=VSP_006240, VSP_006241;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Isoform MEF2 and isoform MEFA are expressed
CC       only in skeletal and cardiac muscle and in the brain. Isoform
CC       RSRFC4 and isoform RSRFC9 are expressed in all tissues examined.
CC   -!- PTM: Constitutive phosphorylation on Ser-408 promotes Lys-403
CC       sumoylation thus preventing acetylation at this site.
CC       Dephosphorylation on Ser-408 by PPP3CA upon neuron depolarization
CC       promotes a switch from sumoylation to acetylation on residue Lys-
CC       403 leading to inhibition of dendrite claw differentiation.
CC       Phosphorylation on Thr-312 and Thr-319 are the main sites involved
CC       in p38 MAPK signaling and activate transcription. Phosphorylated
CC       on these sites by MAPK14/p38alpha and MAPK11/p38beta, but not by
CC       MAPK13/p38delta nor by MAPK12/p38gamma. Phosphorylation on Ser-408
CC       by CDK5 induced by neurotoxicity inhibits MEF2A transcriptional
CC       activation leading to apoptosis of cortical neurons.
CC       Phosphorylation on Thr-312, Thr-319 and Ser-355 can be induced by
CC       EGF.
CC   -!- PTM: Sumoylation on Lys-403 is enhanced by PIAS1 and represses
CC       transcriptional activity. Phosphorylation on Ser-408 is required
CC       for sumoylation. Has no effect on nuclear location nor on DNA
CC       binding. Sumoylated by SUMO1 and, to a lesser extent by SUMO2 and
CC       SUMO3. PIASx facilitates sumoylation in postsynaptic dendrites in
CC       the cerebellar cortex and promotes their morphogenesis (By
CC       similarity).
CC   -!- PTM: Acetylation on Lys-403 activates transcriptional activity.
CC       Acetylated by p300 on several sites in diffentiating myocytes.
CC       Acetylation on Lys-4 increases DNA binding and transactivation (By
CC       similarity). Hyperacetylation by p300 leads to enhanced cardiac
CC       myocyte growth and heart failure.
CC   -!- PTM: Proteolytically cleaved in cerebellar granule neurons on
CC       several sites by caspase 3 and caspase 7 following neurotoxicity.
CC       Preferentially cleaves the CDK5-mediated hyperphosphorylated form
CC       which leads to neuron apoptosis and transcriptional inactivation.
CC   -!- DISEASE: Defects in MEF2A might be a cause of autosomal dominant
CC       coronary artery disease 1 with myocardial infarction (ADCAD1)
CC       [MIM:608320].
CC   -!- SIMILARITY: Belongs to the MEF2 family.
CC   -!- SIMILARITY: Contains 1 MADS-box domain.
CC   -!- SIMILARITY: Contains 1 Mef2-type DNA-binding domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92222.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y16312; CAA76175.1; -; mRNA.
DR   EMBL; X63381; CAA44979.1; -; mRNA.
DR   EMBL; X68503; CAA48516.1; -; mRNA.
DR   EMBL; X68505; CAA48517.1; -; mRNA.
DR   EMBL; U49020; AAB17195.1; -; Genomic_DNA.
DR   EMBL; U44889; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49012; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49013; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49015; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49016; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49017; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49018; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49019; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49020; AAB17196.1; -; Genomic_DNA.
DR   EMBL; U44889; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49012; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49013; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49015; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49016; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49017; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49018; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49019; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; AB208985; BAD92222.1; ALT_INIT; mRNA.
DR   EMBL; BC013437; AAH13437.1; -; mRNA.
DR   IPI; IPI00219254; -.
DR   IPI; IPI00219255; -.
DR   IPI; IPI00398406; -.
DR   IPI; IPI00555797; -.
DR   IPI; IPI00747318; -.
DR   PIR; C39481; C39481.
DR   PIR; S25831; S25831.
DR   RefSeq; NP_001124398.1; NM_001130926.1.
DR   RefSeq; NP_001124399.1; NM_001130927.1.
DR   RefSeq; NP_001124400.1; NM_001130928.1.
DR   RefSeq; NP_001165365.1; NM_001171894.1.
DR   RefSeq; NP_005578.2; NM_005587.2.
DR   UniGene; Hs.268675; -.
DR   PDB; 1C7U; NMR; -; A/B=2-86.
DR   PDB; 1EGW; X-ray; 1.50 A; A/B/C/D=2-78.
DR   PDB; 3KOV; X-ray; 2.90 A; A/B/I/J=2-91.
DR   PDB; 3MU6; X-ray; 2.43 A; A/B/C/D=2-70.
DR   PDB; 3P57; X-ray; 2.19 A; A/B/C/D/I/J=2-91.
DR   PDBsum; 1C7U; -.
DR   PDBsum; 1EGW; -.
DR   PDBsum; 3KOV; -.
DR   PDBsum; 3MU6; -.
DR   PDBsum; 3P57; -.
DR   ProteinModelPortal; Q02078; -.
DR   SMR; Q02078; 2-91.
DR   DIP; DIP-40711N; -.
DR   IntAct; Q02078; 5.
DR   MINT; MINT-104848; -.
DR   STRING; Q02078; -.
DR   PhosphoSite; Q02078; -.
DR   DMDM; 1170908; -.
DR   PRIDE; Q02078; -.
DR   DNASU; 4205; -.
DR   Ensembl; ENST00000346108; ENSP00000284368; ENSG00000068305.
DR   GeneID; 4205; -.
DR   KEGG; hsa:4205; -.
DR   UCSC; uc002bve.1; human.
DR   UCSC; uc002bvf.1; human.
DR   UCSC; uc002bvh.2; human.
DR   CTD; 4205; -.
DR   GeneCards; GC15P100107; -.
DR   H-InvDB; HIX0012611; -.
DR   HGNC; HGNC:6993; MEF2A.
DR   HPA; CAB004499; -.
DR   MIM; 600660; gene.
DR   MIM; 608320; phenotype.
DR   neXtProt; NX_Q02078; -.
DR   eggNOG; COG5068; -.
DR   GeneTree; ENSGT00390000011828; -.
DR   HOGENOM; HBG443633; -.
DR   HOVERGEN; HBG053944; -.
DR   InParanoid; Q02078; -.
DR   KO; K09260; -.
DR   PhylomeDB; Q02078; -.
DR   Pathway_Interaction_DB; p38alphabetadownstreampathway; Signaling mediated by p38-alpha and p38-beta.
DR   Reactome; REACT_111045; Developmental Biology.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_6900; Immune System.
DR   NextBio; 16568; -.
DR   PMAP-CutDB; Q02078; -.
DR   ArrayExpress; Q02078; -.
DR   Bgee; Q59GX4; -.
DR   CleanEx; HS_MEF2A; -.
DR   Genevestigator; Q02078; -.
DR   GermOnline; ENSG00000068305; Homo sapiens.
DR   GO; GO:0000790; C:nuclear chromatin; ISS:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0033613; F:activating transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001105; F:RNA polymerase II transcription coactivator activity; IDA:BHF-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0046332; F:SMAD binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0061337; P:cardiac conduction; ISS:UniProtKB.
DR   GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB.
DR   GO; GO:0048813; P:dendrite morphogenesis; ISS:UniProtKB.
DR   GO; GO:0070375; P:ERK5 cascade; IMP:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0000002; P:mitochondrial genome maintenance; ISS:UniProtKB.
DR   GO; GO:0048311; P:mitochondrion distribution; ISS:UniProtKB.
DR   GO; GO:0007517; P:muscle organ development; NAS:UniProtKB.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0048011; P:nerve growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; TAS:Reactome.
DR   GO; GO:0008063; P:Toll signaling pathway; TAS:Reactome.
DR   GO; GO:0034130; P:toll-like receptor 1 signaling pathway; TAS:Reactome.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; TAS:Reactome.
DR   GO; GO:0034138; P:toll-like receptor 3 signaling pathway; TAS:Reactome.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; TAS:Reactome.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0055005; P:ventricular cardiac myofibril development; ISS:UniProtKB.
DR   InterPro; IPR022102; HJURP_C.
DR   InterPro; IPR002100; TF_MADSbox.
DR   Pfam; PF12347; HJURP_C; 1.
DR   Pfam; PF00319; SRF-TF; 1.
DR   PRINTS; PR00404; MADSDOMAIN.
DR   SMART; SM00432; MADS; 1.
DR   SUPFAM; SSF55455; TF_MADSbox; 1.
DR   PROSITE; PS00350; MADS_BOX_1; 1.
DR   PROSITE; PS50066; MADS_BOX_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Apoptosis;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Disease mutation; DNA-binding; Isopeptide bond; Neurogenesis; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1    507       Myocyte-specific enhancer factor 2A.
FT                                /FTId=PRO_0000199428.
FT   DOMAIN        3     57       MADS-box.
FT   DNA_BIND     58     86       Mef2-type (Potential).
FT   REGION      266    283       Required for interaction with MAPKs.
FT   REGION      289    296       Beta domain.
FT   COMPBIAS      4     31       Lys-rich (basic).
FT   COMPBIAS    141    186       Ser/Thr-rich.
FT   COMPBIAS    420    446       Gln/Pro-rich.
FT   SITE        176    177       Cleavage (Probable).
FT   SITE        213    214       Cleavage (Probable).
FT   SITE        466    467       Cleavage (Probable).
FT   MOD_RES       4      4       N6-acetyllysine (By similarity).
FT   MOD_RES      59     59       Phosphoserine; by CK2 (By similarity).
FT   MOD_RES      98     98       Phosphoserine (By similarity).
FT   MOD_RES     108    108       Phosphothreonine (By similarity).
FT   MOD_RES     114    114       N6-acetyllysine (By similarity).
FT   MOD_RES     117    117       N6-acetyllysine (By similarity).
FT   MOD_RES     235    235       Phosphoserine.
FT   MOD_RES     249    249       N6-acetyllysine.
FT   MOD_RES     254    254       N6-acetyllysine (By similarity).
FT   MOD_RES     255    255       Phosphoserine; by MAPK14.
FT   MOD_RES     270    270       N6-acetyllysine (By similarity).
FT   MOD_RES     282    282       N6-acetyllysine (By similarity).
FT   MOD_RES     312    312       Phosphothreonine; by MAPK7 and MAPK14.
FT   MOD_RES     312    312       Phosphothreonine; by NLK.
FT   MOD_RES     319    319       Phosphothreonine; by MAPK7 and MAPK14.
FT   MOD_RES     355    355       Phosphoserine; by MAPK7.
FT   MOD_RES     403    403       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     408    408       Phosphoserine; by CDK5.
FT   MOD_RES     453    453       Phosphoserine; by MAPK.
FT   CROSSLNK    403    403       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate.
FT   VAR_SEQ      87    132       ALNKKEHRGCDSPDPDTSYVLTPHTEEKYKKINEEFDNMMR
FT                                NHKIA -> TLRKKGLNGCESPDADDYFEHSPLSEDRFSKL
FT                                NEDSDFIFKRGP (in isoform MEFA, isoform
FT                                RSRFC9 and isoform 6).
FT                                /FTId=VSP_006240.
FT   VAR_SEQ     289    296       Missing (in isoform RSRFC4, isoform
FT                                RSRFC9, isoform 5 and isoform 6).
FT                                /FTId=VSP_006241.
FT   VAR_SEQ     420    421       Missing (in isoform RSRFC4 and isoform
FT                                RSRFC9).
FT                                /FTId=VSP_006242.
FT   VARIANT     263    263       N -> S.
FT                                /FTId=VAR_038407.
FT   VARIANT     279    279       P -> L.
FT                                /FTId=VAR_038408.
FT   VARIANT     283    283       G -> D.
FT                                /FTId=VAR_038409.
FT   VARIANT     440    446       Missing (loss of nuclear localization;
FT                                66% decrease in transcription activation;
FT                                loss of synergistic activation by MEF2A
FT                                and GATA1 through a dominant-negative
FT                                mechanism).
FT                                /FTId=VAR_017743.
FT   MUTAGEN     176    176       D->A: Abolishes cleavage at sites 1 and 2
FT                                by caspase 3. Increased cleavage at site
FT                                3 by caspase 3.
FT   MUTAGEN     213    213       D->A: Abolishes cleavage at sites 2 and 3
FT                                by caspase 7.
FT   MUTAGEN     255    255       S->A: Slightly increased MEF2A protein
FT                                level.
FT   MUTAGEN     255    255       S->D: Decreased MEF2A protein level.
FT   MUTAGEN     269    269       R->A: Reduced p38 alpha- and beta2-
FT                                mediated transcriptional activity; when
FT                                associated with A-270.
FT   MUTAGEN     270    270       K->A: Reduced p38 alpha- and beta2-
FT                                mediated transcriptional activity; when
FT                                associated with A-269.
FT   MUTAGEN     273    273       L->A: Reduced p38 alpha- and beta2-
FT                                mediated transcriptional activity; when
FT                                associated with A-275.
FT   MUTAGEN     275    275       V->A: Reduced p38 alpha- and beta2-
FT                                mediated transcriptional activity; when
FT                                associated with A-273.
FT   MUTAGEN     277    277       I->A: Reduced p38 alpha- and beta2-
FT                                mediated transcriptional activity; when
FT                                associated with A-278.
FT   MUTAGEN     278    278       P->A: Reduced p38 alpha- and beta2-
FT                                mediated transcriptional activity; when
FT                                associated with A-277.
FT   MUTAGEN     312    312       T->A: Greatly reduced p38-mediated
FT                                phosphorylation. Abolishes p38-mediated
FT                                transcriptional activation; when
FT                                associated with A-319.
FT   MUTAGEN     319    319       T->A: Greatly reduced p38-mediated
FT                                phosphorylation. Abolishes P38-mediated
FT                                transcriptional activation; when
FT                                associated with A-312.
FT   MUTAGEN     355    355       S->A: No effect on p38-mediated
FT                                transcriptional activity.
FT   MUTAGEN     387    387       S->A: No effect on p38-mediated
FT                                phosphorylation.
FT   MUTAGEN     403    403       K->R: Abolishes sumoylation. No change in
FT                                subcellular location nor in DNA binding.
FT                                Loss of transcriptional repression.
FT   MUTAGEN     408    408       S->A: Loss of sumoylation.
FT   MUTAGEN     408    408       S->D: Rescues sumoylation.
FT   MUTAGEN     453    453       S->A: No effect on p38-mediated
FT                                phosphorylation.
FT   MUTAGEN     479    479       S->A: No effect on p38-mediated
FT                                phosphorylation.
FT   CONFLICT    430    430       Missing (in Ref. 4; AAB17195/AAB17196).
FT   HELIX        14     38
FT   STRAND       42     48
FT   STRAND       54     60
FT   HELIX        62     71
SQ   SEQUENCE   507 AA;  54811 MW;  362BA4FBCC792CE2 CRC64;
     MGRKKIQITR IMDERNRQVT FTKRKFGLMK KAYELSVLCD CEIALIIFNS SNKLFQYAST
     DMDKVLLKYT EYNEPHESRT NSDIVEALNK KEHRGCDSPD PDTSYVLTPH TEEKYKKINE
     EFDNMMRNHK IAPGLPPQNF SMSVTVPVTS PNALSYTNPG SSLVSPSLAA SSTLTDSSML
     SPPQTTLHRN VSPGAPQRPP STGNAGGMLS TTDLTVPNGA GSSPVGNGFV NSRASPNLIG
     ATGANSLGKV MPTKSPPPPG GGNLGMNSRK PDLRVVIPPS SKGMMPPLSE EEELELNTQR
     ISSSQATQPL ATPVVSVTTP SLPPQGLVYS AMPTAYNTDY SLTSADLSAL QGFNSPGMLS
     LGQVSAWQQH HLGQAALSSL VAGGQLSQGS NLSINTNQNI SIKSEPISPP RDRMTPSGFQ
     QQQQQQQQQQ PPPPPQPQPQ PPQPQPRQEM GRSPVDSLSS SSSSYDGSDR EDPRGDFHSP
     IVLGRPPNTE DRESPSVKRM RMDAWVT
//
